According to 2018 Hepatitis B Guidance of the American Association for the Study of Liver Diseases (AASLD), elevation of ALT ≥2, and the ULN with elevated HBV-DNA above 2000 IU/mL should be used as the standard to decide whether a HBeAg-negative chronic hepatitis B patient should receive antiviral treatment. This evidence concerns the gene GPT and chronic hepatitis B virus infection.